AstraZeneca to Build $1.5 Billion Cancer Drug Manufacturing Facility in Singapore

May 20, 2024, 06:51 AM

AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore to enhance its portfolio of antibody-drug conjugates (ADCs). This investment aims to bolster the production of a promising category of cancer-killing drugs. The Anglo-Swedish drugmaker announced the plan on Monday, highlighting its commitment to expanding its capabilities in the oncology sector. The move also signals a shift in the drug industry as companies increasingly split from China.